What's Happening?
Kardigan, a clinical-stage precision therapeutics company, has announced positive results from its Phase 2 clinical trial of tonlamarsen, an antisense oligonucleotide targeting angiotensinogen, in patients with uncontrolled hypertension. The trial demonstrated
a significant reduction in plasma angiotensinogen levels and a clinically meaningful reduction in systolic blood pressure. These findings were presented at the American College of Cardiology’s Annual Scientific Session and published in the Journal of the American College of Cardiology. The trial involved 198 patients and highlighted tonlamarsen's potential as a treatment for acute severe hypertension (ASH) post-hospitalization.
Why It's Important?
The results of this trial are significant as they support the advancement of tonlamarsen into a Phase 2b trial, targeting a high-risk population with acute severe hypertension. This condition affects millions in the U.S. and poses a significant health risk post-hospitalization. Tonlamarsen's ability to modulate the RAAS pathway offers a novel approach to managing blood pressure, potentially reducing the burden on patients who struggle with daily medication adherence. The success of this drug could lead to a new standard of care for hypertension management, impacting healthcare practices and patient outcomes.
What's Next?
Kardigan plans to initiate a Phase 2b clinical trial for tonlamarsen later this year, focusing on patients with acute severe hypertension. The company will continue to explore the drug's efficacy and safety profile, particularly in those with the highest hypertensive burden. As the trial progresses, Kardigan may seek regulatory approval and partnerships to facilitate the drug's development and commercialization. The outcomes of these efforts will be critical in determining tonlamarsen's role in the hypertension treatment landscape.
